Clinical trial
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis
NCT03979456 is registered in ClinicalTrials.gov with Karolinska Institutet as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis
- Lead sponsor
- Karolinska Institutet
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- July 4, 2018
- Completion date
- June 1, 2025
- Enrollment
- 200 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.